Molecular-targeted therapy for advanced anaplastic thyroid cancer combined with nutritional support
Management of anaplastic thyroid cancer (ATC) is often difficult because of its aggressive characteristics. Molecular-targeted therapy was recently introduced as an alternative therapeutic strategy for ATC; lenvatinib is a molecular-targeted agent that is currently indicated only in Japan for the tr...
Main Authors: | Yuka Maegawa, Takashi Higashiguchi, Akihiko Futamura, Norimasa Tsuzuki, Miyo Murai |
---|---|
Format: | Article |
Language: | English |
Published: |
Fujita Medical Society
2019-02-01
|
Series: | Fujita Medical Journal |
Subjects: | |
Online Access: | https://www.jstage.jst.go.jp/article/fmj/5/1/5_2018-003/_pdf/-char/en |
Similar Items
-
Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report
by: Haruhiko Yamazaki, et al.
Published: (2023-03-01) -
Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
by: Dongmei Huang, et al.
Published: (2022-06-01) -
Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
by: Laurys Boudin, et al.
Published: (2022-10-01) -
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
by: Priyanka C. Iyer, et al.
Published: (2018-07-01) -
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
by: Soo Young Kim, et al.
Published: (2020-09-01)